{"id":739,"date":"2016-01-12T16:42:25","date_gmt":"2016-01-12T11:12:25","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=739"},"modified":"2025-05-05T17:09:00","modified_gmt":"2025-05-05T11:39:00","slug":"head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","title":{"rendered":"Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f1c58cda8bb\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f1c58cda8bb\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#DelveInsight_the_leading_market_research_and_consulting_company_has_added_new_report_Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_to_its_portfolio_With_this_launch_Delveinsight_now_has_700_Reports_on_Indication_Pipeline_Insight_In_addition_to_this_our_research_expertise_provides_our_clients_with_up_to_date_information_of_market_till_date_order_has_been_placed\" >DelveInsight, the leading market research and consulting company has added new report&nbsp; Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#The_Indication_pipeline_Insight_Reports_provides_client_with_Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_products_across_the_globe_It_comprehensively_includes\" >The Indication pipeline Insight Reports provides client with Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 products across the globe. It comprehensively includes:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Comparative_study_of_drugs_under_development\" >Comparative study of drugs under development.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Information_on_several_other_drugs_as_well_among_which_10_are_in_phase_III_25_in_phase_II_49_in_phase_I_2_in_phase_0_13_in_pre_%E2%80%93_clinical_and_30_inactive_and_6_are_discontinued\" >Information on several other drugs as well among which 10 are in phase III, 25 in phase II, 49 in phase I, 2 in phase 0 13 in pre &#8211; clinical and 30 inactive and 6 are discontinued.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#R_D_activities_and_technologies_used_along_with_the_pipeline_molecules_in_development\" >R&amp;D activities and technologies used along with the pipeline molecules in development.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Information_related_to_collaborations_in-licensing_and_out-licensing_deals\" >Information related to collaborations, in-licensing and out-licensing deals.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Stages_of_development_of_pipeline_molecules\" >Stages of development of pipeline molecules.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Therapeutic_assessments_by_molecule_types_route_of_administration_monotherapy_and_combination_products\" >Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_Report_envisages_Pipeline_Intelligence_by_identifying_the_key_players_along_with_their_potential_pipeline_molecule_Therefore_DelveInsights_report_on_Head_and_Neck_Squamous_Cell_Carcinoma_helps_to_optimize_portfolio_by_creating_effective_counter-strategies_to_gain_competitive_and_therapeutic_advantage_in_global_Pharma_market_In_addition_it_assesses_the_major_market_drivers_and_barriers_in_development_of_Pipeline_molecules_which_helps_to_understand_market_for_collaborations_and_licensing_deals\" >Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight\u2019s report on&nbsp;Head and Neck Squamous Cell Carcinoma&nbsp;helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#DelveInsight_is_offering_the_Report_at_a_price_of_US_2250_as_a_single_user_license_USD_4500_as_a_site_license_and_USD_6750_as_a_GlobalEnterprise_License\" >DelveInsight is offering the Report at a price of US 2,250 as a single user license, USD 4,500 as a site license and USD 6,750 as a Global\/Enterprise License.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#For_more_information_on_Pipeline_Insight_Reports_email_at_infodelveInsightcom\" >For more information on Pipeline Insight Reports, email at info@delveInsight.com<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#About_Us\" >About Us:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\/#DelveInsight_is_a_leading_Business_Consulting_and_Market_Research_Firm_We_help_our_clients_to_find_answers_relevant_to_their_business_facilitating_decision-making_identify_potential_market_opportunities_competitor_assessments_and_business_environmental_assessment_In_addition_to_this_DelveInsight_also_deals_in_providing_custom_research_services_in_coherence_with_interest_area_of_the_clients\" >DelveInsight is a leading Business Consulting and Market Research Firm.&nbsp; We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/a><\/li><\/ul><\/nav><\/div>\n<h6><span class=\"ez-toc-section\" id=\"DelveInsight_the_leading_market_research_and_consulting_company_has_added_new_report_Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_to_its_portfolio_With_this_launch_Delveinsight_now_has_700_Reports_on_Indication_Pipeline_Insight_In_addition_to_this_our_research_expertise_provides_our_clients_with_up_to_date_information_of_market_till_date_order_has_been_placed\"><\/span>DelveInsight, the leading market research and consulting company has added new report&nbsp; Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"The_Indication_pipeline_Insight_Reports_provides_client_with_Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_products_across_the_globe_It_comprehensively_includes\"><\/span>The Indication pipeline Insight Reports provides client with Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 products across the globe. It comprehensively includes:<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><\/h6>\n<ul>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Comparative_study_of_drugs_under_development\"><\/span>Comparative study of drugs under development.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Information_on_several_other_drugs_as_well_among_which_10_are_in_phase_III_25_in_phase_II_49_in_phase_I_2_in_phase_0_13_in_pre_%E2%80%93_clinical_and_30_inactive_and_6_are_discontinued\"><\/span>Information on several other drugs as well among which <strong><em>10 are in phase III, 25 in phase II, 49 in phase I, 2 in phase 0 13 in pre &#8211; clinical and 30 inactive and 6 are discontinued.<\/em><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"R_D_activities_and_technologies_used_along_with_the_pipeline_molecules_in_development\"><\/span>R&amp;D activities and technologies used along with the pipeline molecules in development.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Information_related_to_collaborations_in-licensing_and_out-licensing_deals\"><\/span>Information related to collaborations, in-licensing and out-licensing deals.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Stages_of_development_of_pipeline_molecules\"><\/span>Stages of development of pipeline molecules.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<li>\n<h6><span class=\"ez-toc-section\" id=\"Therapeutic_assessments_by_molecule_types_route_of_administration_monotherapy_and_combination_products\"><\/span>Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<\/li>\n<\/ul>\n<h6><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"Head_and_Neck_Squamous_Cell_Carcinoma_-Pipeline_Insights_2016_Report_envisages_Pipeline_Intelligence_by_identifying_the_key_players_along_with_their_potential_pipeline_molecule_Therefore_DelveInsights_report_on_Head_and_Neck_Squamous_Cell_Carcinoma_helps_to_optimize_portfolio_by_creating_effective_counter-strategies_to_gain_competitive_and_therapeutic_advantage_in_global_Pharma_market_In_addition_it_assesses_the_major_market_drivers_and_barriers_in_development_of_Pipeline_molecules_which_helps_to_understand_market_for_collaborations_and_licensing_deals\"><\/span>Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight\u2019s report on&nbsp;Head and Neck Squamous Cell Carcinoma&nbsp;helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<p>&nbsp;<\/p>\n<h6><span class=\"ez-toc-section\" id=\"DelveInsight_is_offering_the_Report_at_a_price_of_US_2250_as_a_single_user_license_USD_4500_as_a_site_license_and_USD_6750_as_a_GlobalEnterprise_License\"><\/span>DelveInsight is offering the Report at a price of US 2,250 as a single user license, USD 4,500 as a site license and USD 6,750 as a Global\/Enterprise License.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"For_more_information_on_Pipeline_Insight_Reports_email_at_infodelveInsightcom\"><\/span>For more information on Pipeline Insight Reports, email at <a href=\"mailto:info@delveInsight.com\">info@delveInsight.com<\/a><span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"About_Us\"><\/span>About Us:<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h6><span class=\"ez-toc-section\" id=\"DelveInsight_is_a_leading_Business_Consulting_and_Market_Research_Firm_We_help_our_clients_to_find_answers_relevant_to_their_business_facilitating_decision-making_identify_potential_market_opportunities_competitor_assessments_and_business_environmental_assessment_In_addition_to_this_DelveInsight_also_deals_in_providing_custom_research_services_in_coherence_with_interest_area_of_the_clients\"><\/span>DelveInsight is a leading Business Consulting and Market Research Firm.&nbsp; We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight, the leading market research and consulting company has added new report&nbsp; Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[180,204,280,356,386,477,479],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-739","post","type-post","status-publish","format-standard","hentry","category-articles","tag-competitive-landscape","tag-delveinsight","tag-head-and-neck-squamous-cell-carcinoma","tag-licensing-opportunities","tag-market-trends","tag-pipeline","tag-pipeline-coverage","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Head and Neck Squamous Cell Carcinoma Pipeline | DelveInsight<\/title>\n<meta name=\"description\" content=\"The Indication Pipeline Insight Reports Provides Client With Head And Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Products Across The Globe\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Head and Neck Squamous Cell Carcinoma Pipeline | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The Indication Pipeline Insight Reports Provides Client With Head And Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Products Across The Globe\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-01-12T11:12:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:39:00+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Head and Neck Squamous Cell Carcinoma Pipeline | DelveInsight","description":"The Indication Pipeline Insight Reports Provides Client With Head And Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Products Across The Globe","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","og_locale":"en_US","og_type":"article","og_title":"Head and Neck Squamous Cell Carcinoma Pipeline | DelveInsight","og_description":"The Indication Pipeline Insight Reports Provides Client With Head And Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Products Across The Globe","og_url":"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-01-12T11:12:25+00:00","article_modified_time":"2025-05-05T11:39:00+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","url":"https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016","name":"Head and Neck Squamous Cell Carcinoma Pipeline | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2016-01-12T11:12:25+00:00","dateModified":"2025-05-05T11:39:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Indication Pipeline Insight Reports Provides Client With Head And Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Products Across The Globe","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/head-and-neck-squamous-cell-carcinoma-pipeline-insights-2016"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Head and Neck Squamous Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline coverage<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Head and Neck Squamous Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pipeline coverage<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Jan 12, 2016","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Jan 12, 2016 4:42 pm","modified":"Updated on May 5, 2025 5:09 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=739"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/739\/revisions"}],"predecessor-version":[{"id":31662,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/739\/revisions\/31662"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=739"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=739"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}